Results 13,281-13,300 of 21,090 for speaker:Alan Kelly
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: An average figure is fine, but what is the longest period for any individual?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Why was that?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Does the HSE have contractual obligations that the laboratories have to honour? One should not have to wait for 70 days for slides. In a period of 70 days the health issues for a woman in these circumstances could range from fairly serious to who knows what. They are entitled to them.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: It is their human right. Having to wait for 70 days is just unacceptable and beyond commentary.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Why, in some cases, did solicitors representing clients have to go to court to escalate the matter?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: I will come back to it. I want to ask the Department of Health about when the decision was made to offer free screening to all women. The Committee of Public Accounts would like to know how much it is going to cost. In fairness to him, the Minister for Health, Deputy Harris, made the decision for the right reasons, but there may be questions as to whether it was the right one. I...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: To be honest, I know what they are. From a departmental point of view, we do not have answers to those two questions.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: That is a pity because it a fairly important point.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Let us be honest, the Department of Health is watching the proceedings. Can we publicly ask it to answer my two questions?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Can someone from the Department, on behalf of colleagues in front of the committee, please, furnish the information on the cost of free screening and the advice received from the Department?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: If Mr. McCallion does not mind, there is a pathway in this questioning. In fairness to him, his answers are very transparent. We now know that between May and September, there were almost 42,500 repeat screenings and that 86,000 samples have been progressed. Is that correct?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: I understand the differential. The issue I am trying to get to is that we now know publicly that there is a big backlog. What is the extent of the backlog? It runs to how many thousands?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: We are getting there.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Being honest, that is as a direct result of the fact that there is now free smear testing.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: That is good.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: That is also good. There are pluses and minuses. I understand that.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: When the decision was made to go down this route, it was to cause an avalanche and we all know why. There is no way I am making a political point because the circumstances were quite unique and I just want to get to the facts. As a consequence, what was the resource differential or what capacity was created to deal with the issue?
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: I understand that. I have read a lot about the issue. We have gone from a delay two weeks ago of 18 weeks to 20 weeks.
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: There are two or more steps. First, the resources being put in from a HSE perspective in bringing forward HPV testing have to include similar people in some way. Are the resources being put in undertaking the more immediate task - finding capacity to deal with the issue - the same as those being put in in providing HPV testing? Is this going to affect the roll-out and timeline for...
- Public Accounts Committee: Matters related to Medical Negligence, Open Disclosure, Cervical Cancer and Thalidomide Litigation (8 Nov 2018)
Alan Kelly: Mr. McCallion has been most eloquent, but I think this is a huge risk. I think there is a significant overlap. I do not think there are enough resources and that will affect the roll-out of HPV testing. When it comes to the backlog, some of the women who were triaged cases may have to go back for screening sooner than others. Some women might be asked to come back because of potential...